difficult to draw firm conclusions. In addition, few studies have analyzed CvRFs, HIV-related parameters, and treatment together. Here we investigate the role of HIV virological and immunological parameters, in addition to CvRFs and ART exposure, on the risk of MI in HIV-infected individuals, in a country with a low incidence of MI in the general population [26] .
METHODS

Study Population
We conducted a case-control study within the French Hospital Database on HIV (FHDH)-ANRS CO4, an ongoing, prospective observational hospital-based cohort, allowing to obtain estimates from a sample of the cohort that are similar to estimates obtained from analysis of the entire cohort [27, 28] . This design allows accounting for time-varying confounders [29] and preserves all advantages of cohort studies, while avoiding the potential biases of conventional case-control studies [30] . The cohort comprised data on a total of 74 958 patients who had be seen at least once between 2000 and 2006, for a total follow-up of 298 156 patient-years [31] . All participating HIVinfected individuals provided written informed consent, and the cohort was approved by the Commission Nationale Informatique et Liberté in accordance with French law.
Case patients were patients who had a first prospectively reported MI between January 2000 and December 2006. Patients with a history of an earlier MI were excluded. The diagnosis of MI was confirmed by a cardiologist who was provided with cardiac signs and symptoms, troponin and/or creatine kinase levels, and electrocardiographic findings, as recorded in the medical records. We used the American College of Cardiology/European Society of Cardiology definition of MI [32] . Definite and probable cases of MI and possible deaths from MI were included. The index date was the date of MI diagnosis.
Controls were HIV-infected individuals with no history of MI and no diagnosis evocative of MI (medical records did not mention electrocardiographic abnormalities or chest pain), who had already been enrolled in the database when MI was diagnosed in the corresponding case patient (±6 months). They were also matched with the case patients for age (±3 years) at MI diagnosis, sex, and the clinical center. With the aim of having 3 controls per case patient, we randomly selected, using incidence-density sampling, up to 5 controls per case patient from the list of patients meeting the matching criteria. Case patients were eligible as controls up to the onset of MI.
Data Collection
The following data were collected from the medical records: family history of premature coronary artery disease (CAD), hypertension with a recorded date of diagnosis, antihypertensive medication, diabetes with a recorded date of diagnosis, antidiabetic treatment, fasting glucose level, hypercholesterolemia with a recorded date of diagnosis, lipid-lowering drug therapy (statins and/or fibrates), total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol levels, hypertriglyceridemia with a recorded date of diagnosis, triglyceride level, and smoking status with the smoking cessation date if relevant. We also collected data on current use of cocaine and/or intravenous drugs [33] , as well as height and weight to determine the body mass index (BMI) [34] . To study the impact of HIV infection on the risk of MI, CD4 and CD8 T-cell counts, CD4 T-cell nadir, plasma HIV-1 RNA level, and AIDS status [35] were verified. The detailed history of ART prescribed up to the index date was also verified. All biological parameters were collected within 3 months before the index date.
Statistical Analysis
The aim was to identify independent predictors of MI in HIV-infected individuals among the variables listed in Appendix Table 2 . As some parameters with missing data, such as a family history of premature CAD, are known to influence the risk of CVD, and because it is better to impute missing data than to ignore them [36] , we created 20 data sets in which missing data were imputed from each patient's other covariables, including demographic, biological, and therapeutic data; CVD risk factors; and inclusion as a case patient or a control. In these imputations, missing values were randomly sampled from their predicted distributions [37, 38] . Analyses were run on each of the 20 data sets, including the imputed values, and the results were combined with Rubin's rules [38] . For each continuous variable, the choice between continuous and categorical classification was based on the lowest value of Akaike's information criterion (AIC) for the corresponding univariate conditional logistic regression model. The best way of modeling each variable is indicated by an asterisk in Appendix Table 2 . For example, the CD4 T-cell nadir was best modeled as a continuous variable after log 2 transformation. Exposure to ART was taken into account as cumulative exposure to thymidine analogs, abacavir, didanosine, tenofovir, emtricitabine, lamivudine, zalcitabine, efavirenz, nevirapine, and all PIs. To avoid the colinearity problem in the models, the different variables linked to a given entity were grouped together in a family (eg, glucose metabolism and treatment), as recommended elsewhere [39] . Then each variable in a given family was entered in a stepwise multivariable model, and variables with P values <.10 were retained. The variables retained at this stage are indicated in bold type in Appendix Table 2 (eg, plasma HIV-1 RNA: ≤50 and >50 [copies/mL]). Finally, a multivariable model adjusted for all the selected variables was constructed. This analytical strategy and the variables used were different from those used in our previous study, which examined the potential role of treatment exposures with the aim of controlling confounders [7] . SAS software, version 9.1, was used for all statistical analyses.
RESULTS
Characteristics of the Patients
Of 74 958 patients, the study population consisted of 289 case patients and 884 controls [7] , 246 case patients had 3 controls, 29 had >3 controls, and 14 had <3 controls. The diagnosis of MI was definite in 215 of case patients (74%) and probable in 48 (17%), and 26 case patients (9%) died of possible MI. As shown in Table 1 , all traditional CvRFs were more frequent in case patients than in controls. BMIs were significantly higher in controls than in case patients (22.8 . Cocaine and/or intravenous drug use was more frequent in case patients than in controls (13% vs 9%; P = .041). The HIV-1 RNA level was ≤50 copies/mL in 43% of case patients and 52% of controls, and the respective median levels were 127 copies/mL (IQR, 50-3900) and 50 copies/mL (IQR, 50-1368) (P = .015). Case patients had a significantly lower CD4 T-cell nadir than controls (P = .002), whereas there was no significant difference in the current CD4 T-cell count. More case patients (40.1%) than controls (30.4%) had a CD8 T-cell count >1150/mm 3 and an AIDS-defining illness before the index date (P = .003). (Table 1) . Following the method described in the statistical analysis section, the final model took into account smoking status, the family history of premature CAD, hypertension, hypercholesterolemia, the HDL cholesterol level, diabetes, the BMI, cocaine and/or intravenous drug use, the plasma HIV-1 RNA level, the CD4 T-cell nadir and CD8 T-cell count, and cumulative exposure to PIs (Appendix Table 2 ).
Impact of Cardiovascular Risk Factors
In the final multivariable conditional regression model ( Figure 1 
Impact of ART
In the final multivariable conditional regression model, cumulative exposure to all studied PIs was associated with a higher risk of MI, with an OR of 2.23 per 10 years of exposure (95% CI, 1.17-4.24) (Figure 1 ). Cumulative exposure to any other ART was not significantly associated with the risk of MI. In a post hoc sensitivity analysis, current exposure to abacavir was not associated with a higher risk of MI, with an OR of 1.17 (95% CI, .81-1.68), and for the other variables included in the model, the ORs were similar to those of the final model. In post hoc sensitivity analyses, including either cumulative exposure to each antiretroviral, or including only patients under treatment at index date, the ORs for the other variables accounted for were also similar (data not shown).
Impact of HIV Virological and Immunological Parameters
A current HIV-1 RNA level >50 copies/mL was associated with an increased risk of MI (OR, 1.51; 95% CI, 1.09-2.10) (Figure 1 ). The estimated OR for the risk of MI per log 2 increase in the CD4 T-cell nadir was 0.90 (95% CI, .83-0.97) for the highest tertile of the current CD8 T-cell count and 1.48 (95% CI, 1.01-2.18) for the lowest (model AIC, 654.43). In post hoc sensitivity analyses, when the HIV-1 RNA level was included as a continuous variable after log 10 transformation, the OR for this variable was 1.08 (95% CI, 1.02-1.14). Of note, when the ratio of the CD4 T-cell nadir to the current CD8 T-cell count is used in the model, rather than the 2 separate variables, the association was slightly more significant, with an OR of 0.30 (95% CI, .13-.72) (model AIC, 653.27). The ORs for the other variables were not modified in the 2 analyses.
DISCUSSION
We conducted a nested case-control study within a large database of HIV-infected individuals to study the influence of HIV virological and immunological parameters on the risk of MI, independently of the exposure to ART and traditional CvRFs. We found that an HIV-1 RNA level >50 copies/mL, a low CD4 T-cell nadir, and a high current CD8 T-cell count were significantly associated with an increased risk of MI. The CD4 T-cell nadir/current CD8 T-cell count ratio was a slightly better predictor of the risk of MI. All cases were validated, and the study was large. The frequency of missing data was noteworthy for 3 CvRFs: the family history of premature CAD, the HDL cholesterol level, and the LDL cholesterol level. This is not uncommon in HI-V-infected patient cohorts. For instance, in an article on the D:A:D study by Law et al, on predicting the risk of CVD in HIV-infected individuals, 48% of patients had missing data [19] . In our study, results of sensitivity analyses showed that the ORs of interest (ie, for HIV replication and immune status) were not sensitive to the way in which these missing data were handled (Appendix Table 3 ). In the FHDH, the estimated rate of patients lost to follow-up is 5.4%; one-third of these patients had died [40] . Given the design of the study, the potential impact of this rate is probably smaller than it would be for a cohort analysis. As expected [3, 6, 41, 42] , we found that traditional CvRFs (smoking; hypertension and hypercholesterolemia) were associated with an increased risk of MI. A family history of premature CAD [43] , did not significantly increase the risk of MI in our study. A high HDL cholesterol level [44, 45] tended to reduce the risk of MI. The lack of statistical significance for both these latter variables was probably due in part to the high frequency of missing data. Diabetes was not associated with the risk of MI in our study. The impact of diabetes on CVD may depend on sex, age and diabetes duration. Diabetes is a stronger risk factor for CVD in women than in men [46] , and its impact becomes apparent only after many years [47] . Most of the patients in our study were men and <50 years old, which may explain why we did not find an association between diabetes and the risk of MI. As the case patients and controls were matched for age and sex, we were unable to study the influence of these 2 factors. However, we have already reported the influence of age and sex on the risk of MI in HIV-infected individuals [48] .
BMIs <21 kg/m 2 was significantly associated with an increased risk of MI in our population, whereas obesity is a known risk factor for MI in the general population [49, 50] . In a recent report [51] comparing HIV-infected and uninfected individuals with a first episode of acute coronary syndrome, BMI was higher in the latter than in the former. It is conceivable that changes in body fat distribution in HIV-infected individuals before and after the ART era could explain this result [52] . The waist-hip ratio better reflects fat distribution and could thus be a better predictor than BMI of cardiovascular events in HIVinfected individuals [50, 53] . Unfortunately, these values are not systematically noted in the medical records. We found that cumulative exposure to PIs was associated with an increased risk of MI. The impact of ART on the risk of MI was similar to other studies [5, 7] . In sensitivity analyses that included current exposure to abacavir or exposure to each antiretroviral drug, the results on HIV replication and immune status did not change.
Previous studies with clinical end points (MI, death, composite end point) or surrogate end points (IMT, coronary computed tomography angiography, pulse wave velocity, brachial artery flow-mediated dilatation, etc.) did not systematically examine the impact of HIV virological and immunological parameters on the risk of CVD. In addition, they did not use the same end points or the same approach to account for the different variables. It is therefore difficult to compare the results of the different studies. We have chosen to summarize only published studies with clinical end points [9, 11, [17] [18] [19] [20] [21] [22] [23] [24] [25] (Appendix Table 1 ) because we cannot be certain that the risk factors are the same for clinical and surrogate end points. Only 4 studies with clinical end points considered HIV-1 RNA levels as a risk factor for MI, CVD, or dying of CVD [11, 17, 20, 21] . In the Strategies for Management of Antiretroviral Therapy (SMART) study, the plasma HIV-1 RNA level was associated with an increased risk of MI only when the model was not adjusted for the CD4 T-cell count, probably because of colinearity between these variables [21] . Marin et al found that a plasma HIV-1 RNA level >100 000 copies/mL was associated with an increased risk of dying from CVD [11] . Friis-Møller et al and Triant et al did not find an association between the risk of MI and the plasma HIV-1 RNA level expressed as a continuous variable [17, 20] . We found that the current plasma HIV-1 RNA level, expressed either as a categorical or as a continuous variable, was associated with an increased risk of MI, illustrating the beneficial impact of ART on the risk of MI, as shown in the SMART trial [10] . The differences between the studies could be explained by differences in the proportion of patients with controlled viral load, or by a power issue.
We found that a low CD4 T-cell nadir and a high current CD8 T-cell count were independent predictors of MI, contrary to the current CD4 T-cell count. Triant et al found that a CD4 T-cell count <200/mL was associated with an increased risk of MI [17] , while Kaplan et al found that it was associated with increased carotid IMT [13] . These results do not contradict each other, because a low current CD4 T-cell count is indicative of a low CD4 T-cell nadir. Concerning the CD4 T-cell count, 3 studies did not find an association in multivariable analyses [11, 20, 21] , and other studies did not examine or did not report the association with the chosen end point [9, 18, 19, [22] [23] [24] [25] . Few studies have examined the influence of the CD4 T-cell nadir [12, 13, 15, 17] . The CD4 T-cell nadir may reflect the length of time during which HIV replicated freely, thus damaging the immune system, and has been linked to persistent immune activation even in patients with controlled viral load [54, 55] , which may explain its association with the risk of MI.
To our knowledge, no previous studies with clinical end points have examined the potential influence of the CD8 Tcell count. However, some studies with surrogate end points have shown that the risk of MI is associated with the CD4/ CD8 T-cell ratio [12] or other activation markers [12, 14, 15] . The CD8 T-cell count could reflect persistent immune activation, although this has not been clearly demonstrated.
In summary, we found that a low CD4 T-cell nadir, a current CD8 T-cell count over 1150/mm 3 and a plasma HIV-1 RNA level >50 copies/mL are independently associated with the risk of MI in HIV-infected individuals. These findings support early diagnosis and treatment of HIV infection and call for studies of interventions designed to diminish persistent immune activation in patients with controlled viral loads.
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